SG11202104356VA - Bt1718 for use in treating cancer - Google Patents
Bt1718 for use in treating cancerInfo
- Publication number
- SG11202104356VA SG11202104356VA SG11202104356VA SG11202104356VA SG11202104356VA SG 11202104356V A SG11202104356V A SG 11202104356VA SG 11202104356V A SG11202104356V A SG 11202104356VA SG 11202104356V A SG11202104356V A SG 11202104356VA SG 11202104356V A SG11202104356V A SG 11202104356VA
- Authority
- SG
- Singapore
- Prior art keywords
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862753005P | 2018-10-30 | 2018-10-30 | |
US201962788391P | 2019-01-04 | 2019-01-04 | |
US201962907106P | 2019-09-27 | 2019-09-27 | |
PCT/GB2019/053080 WO2020089627A1 (en) | 2018-10-30 | 2019-10-30 | Bt1718 for use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104356VA true SG11202104356VA (en) | 2021-05-28 |
Family
ID=68468771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104356VA SG11202104356VA (en) | 2018-10-30 | 2019-10-30 | Bt1718 for use in treating cancer |
Country Status (8)
Country | Link |
---|---|
US (3) | US20200129630A1 (en) |
EP (1) | EP3873609A1 (en) |
JP (1) | JP2022514121A (en) |
AU (1) | AU2019370807A1 (en) |
CA (1) | CA3116504A1 (en) |
IL (1) | IL282663A (en) |
SG (1) | SG11202104356VA (en) |
WO (1) | WO2020089627A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170073611A (en) | 2014-10-29 | 2017-06-28 | 바이시클 테라퓨틱스 리미티드 | Bicyclic peptide ligands specific for mt1-mmp |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
WO2018127699A1 (en) | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
EP3615550A1 (en) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
CN112955459A (en) | 2018-10-23 | 2021-06-11 | 拜斯科技术开发有限公司 | Bicyclic peptide ligands and uses thereof |
TW202108165A (en) | 2019-05-10 | 2021-03-01 | 英商拜西克爾德有限公司 | Methods for treating cancer |
CN111876384B (en) * | 2020-07-31 | 2022-03-11 | 江苏莱森生物科技研究院有限公司 | Tumor tissue implantation liquid and preparation method and application thereof |
US20230253079A1 (en) * | 2022-02-08 | 2023-08-10 | Akyrian Systems LLC | CLINICAL TRIAL VERIFICATION SYSTEM AND METHOD IMPROVEMENT INCLUDING A COMBINED SCREENSHARING, VIDEO CONFERENCING, SOURCE CAPTURE AND eCRF/CLINICAL TRIAL DOCUMENT RECONCILIATION SYSTEM |
CN115382119B (en) * | 2022-08-30 | 2024-03-12 | 湖南半岛医疗科技有限公司 | Pulse output control method and therapeutic apparatus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170073611A (en) * | 2014-10-29 | 2017-06-28 | 바이시클 테라퓨틱스 리미티드 | Bicyclic peptide ligands specific for mt1-mmp |
WO2018096365A1 (en) * | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
-
2019
- 2019-10-30 AU AU2019370807A patent/AU2019370807A1/en active Pending
- 2019-10-30 EP EP19798356.2A patent/EP3873609A1/en active Pending
- 2019-10-30 SG SG11202104356VA patent/SG11202104356VA/en unknown
- 2019-10-30 CA CA3116504A patent/CA3116504A1/en active Pending
- 2019-10-30 JP JP2021547957A patent/JP2022514121A/en active Pending
- 2019-10-30 US US16/668,481 patent/US20200129630A1/en not_active Abandoned
- 2019-10-30 WO PCT/GB2019/053080 patent/WO2020089627A1/en unknown
-
2021
- 2021-04-26 IL IL282663A patent/IL282663A/en unknown
-
2022
- 2022-07-11 US US17/861,838 patent/US20230165966A1/en not_active Abandoned
-
2023
- 2023-11-07 US US18/503,815 patent/US20240181069A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240181069A1 (en) | 2024-06-06 |
WO2020089627A1 (en) | 2020-05-07 |
US20200129630A1 (en) | 2020-04-30 |
JP2022514121A (en) | 2022-02-09 |
AU2019370807A1 (en) | 2021-05-20 |
IL282663A (en) | 2021-06-30 |
US20230165966A1 (en) | 2023-06-01 |
CA3116504A1 (en) | 2020-05-07 |
EP3873609A1 (en) | 2021-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201904695B (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
IL282663A (en) | Bt1718 for use in treating cancer | |
IL271221A (en) | Il-1beta binding antibodies for use in treating cancer | |
IL271019A (en) | Tinostamustine for use in treating ovarian cancer | |
PL3534885T3 (en) | Farnesyltransferase inhibitors for use in treating cancer | |
IL282294A (en) | Combinations for immune-modulation in cancer treatment | |
ZA201804361B (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
IL259510A (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
SG11202010528XA (en) | Combinations for treating cancer | |
IL280830A (en) | Conjugates for use in methods of treating cancer | |
EP3708173C0 (en) | Pharmaceutical composition comprising mirna-3140 for use in treating cancer | |
IL262143A (en) | Improvements in cancer treatment | |
IL261648A (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
IL259358A (en) | Bis-pyridazine compounds and their use in treating cancer | |
IL258644A (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
IL269121A (en) | Usl-311 for use in the treatment of cancer | |
IL285538A (en) | Combination therapies for use in treating cancer | |
GB201819920D0 (en) | Cancer treatment | |
SI3518911T1 (en) | Rad1901 for use in treating ovarian cancer | |
GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
PT3813832T (en) | Compounds for use in preventing or treating cancer | |
GB201819026D0 (en) | Means and methods for treating cancer | |
GB201811431D0 (en) | Cancer treatment | |
GB201804816D0 (en) | Cancer treatment |